Related Experiment Video
Updated: Jul 8, 2026

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
Published on: March 23, 2022
Marfan syndrome-diagnosis and management
Naser M Ammash1, Thoralf M Sundt, Heidi M Connolly
1Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. ammash.naser@mayo.edu
Abstract:
Marfan syndrome (MFS) is the most common inherited disorder of connective tissue that affects multiple organ systems. This autosomal-dominant condition has an incidence of 2-3 per 10,000 individuals. Although genetic testing is available, the diagnosis is still primarily made using the Ghent criteria. Early identification and appropriate management is critical for patients with MFS who are prone to the life-threatening cardiovascular complications of aortic dissection and rupture. Advances in the understanding of the cause of MFS, early recognition of the disorder, and subsequent institution of medical and surgical therapy has resulted in dramatic improvement in the prognosis of this patient population over the past few decades. Beta-blockers have been demonstrated to slow aortic growth and thus delay the time to aortic surgery. Operative intervention has markedly changed the prognosis of patients with MFS and can be safely performed on an elective basis. Identification of presymptomatic patients is critical to reduce the frequency of catastrophic aortic events.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Mitral Stenosis III: Medical Management
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation IV: Nursing Management
Mitral Stenosis IV: Nursing Management